Title :

Duration of preclinical, prodromal, and dementia stages of alzheimer''s disease in relation to age, sex, and apoe genotype

Author(s) :

Vermunt, Lisa [Auteur]
Sikkes, Sietske A. M. [Auteur]
Van Den Hout, Ardo [Auteur]
Handels, Ron [Auteur]
Bos, Isabelle [Auteur]
Van Der Flier, Wiesje M. [Auteur]
Kern, Silke [Auteur]
Ousset, Pierre-Jean [Auteur]
Maruff, Paul [Auteur]
Skoog, Ingmar [Auteur]
Verhey, Frans R. J. [Auteur]
Freund-Levi, Yvonne [Auteur]
Tsolaki, Magda [Auteur]
Wallin, Asa K. [Auteur]
Olde-Rikkert, Marcel G. M. [Auteur]
Soininen, Hilkka [Auteur]
Spiru, Luisa [Auteur]
Zetterberg, Henrik [Auteur]
Blennow, Kaj [Auteur]
Scheltens, Philip [Auteur]
Muniz-Terrera, Graciela [Auteur]
Visser, Pieter Jelle [Auteur]

Journal title :

Alzheimer's & dementia . the journal of the Alzheimer's Association

Abbreviated title :

Alzheimers Dement

Publication date :

2019-06-01

ISSN :

1552-5279

English keyword(s) :

Multistate model
APOE
Clinical setting
Progression
Dementia
Prodromal
Preclinical
Disease duration
Alzheimer''s disease

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid ...
Show more >BACKGROUND: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. METHODS: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. RESULTS: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. CONCLUSIONS: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:30:13Z